Piper Still Believes In Arcturus Vaccine After 'Underwhelming' Immunogenicity

Piper Sandler analyst Yasmeen Rahimi keeps an Overweight rating on Arcturus Therapeutics with a $140 price target after the company announced Phase 1/2 dataset for its STARR self-replicating mRNA COVID-19 vaccine, ARCT-021.